Actualités Generation Uranium Inc - GEN | Actions TSX Venture Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Daratumumab Granted Fast Track Designation From U.S. Food and Drug Administration

Company Announcement Daratumumab receives Fast Track designation in double refractory multiple myeloma Potential for expedited...

Arzerra Receives Approval in Japan

Company Announcement Arzerra(r) approved in Japan for relapsed / refractory CLL Genmab to receive DKK 20 million milestone payment...

Genmab 2012 Annual Report

COPENHAGEN, Denmark, March 7, 2013 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2012. Below is a summary...

Genmab Announces Sale of Manufacturing Facility to Baxter

Company Announcement Genmab sells manufacturing facility to Baxter Healthcare Corporation Genmab receives USD 10 million COPENHAGEN...

Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures

Company Announcement Arzerra worldwide net sales in Q4 2012 totaled GBP 14.5 million Full year 2012 Arzerra sales were GBP 60 million...

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Genmab A/S...

Genmab Unveils a New Antibody Technology Platform: HexaBody

Company Announcement HexaBody platform is a novel technology platform to potently enhance antibody therapeutics Multiple new business...

Genmab Reaches Third Milestone in Lundbeck Collaboration

Company Announcement Third pre-clinical milestone met in Lundbeck collaboration [Eur]1 million milestone payment to Genmab...

Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

Company Announcement Genmab reaches key milestone in DuoBody® platform collaboration with Janssen $2 million milestone payment to...

New Preliminary Efficacy Data for Daratumumab Presented at ASH

Company Announcement Preliminary safety and efficacy data from final patients in part 1 of study continue to be encouraging Data...

Genmab Announces DuoBody Platform Collaboration With Kyowa Hakko Kirin

Company Announcement - DuoBody® research collaboration with Kyowa Hakko Kirin - Genmab's fourth DuoBody technology collaboration COPENHAGEN...

CORRECTION: Genmab Announces Financial Results for the First Nine Months of 2012 and Improves 2012 Financial Guidance

COPENHAGEN, Denmark, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Interim Report for the 9 Months Ended September 30, 2012 Company...

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

COPENHAGEN, Denmark, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Interim Report for the 9 Months Ended September 30, 2012 Company...

Arzerra Third Quarter 2012 Net Sales Figures

Company Announcement - Arzerra worldwide net sales in Q3 2012 totaled GBP 18.2 million - Genmab expects royalty payment of DKK 34 million...

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Genmab A/S...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

GEN Actualités

Daratumumab Granted Fast Track Designation From U.S. Food and Drug Administration

Arzerra Receives Approval in Japan

Genmab 2012 Annual Report

Genmab Announces Sale of Manufacturing Facility to Baxter

Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures

Major Shareholder Announcement

Genmab Unveils a New Antibody Technology Platform: HexaBody

Genmab Reaches Third Milestone in Lundbeck Collaboration

Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

New Preliminary Efficacy Data for Daratumumab Presented at ASH

Genmab Announces DuoBody Platform Collaboration With Kyowa Hakko Kirin

CORRECTION: Genmab Announces Financial Results for the First Nine Months of 2012 and Improves 2012 Financial Guidance

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

Arzerra Third Quarter 2012 Net Sales Figures

Major Shareholder Announcement

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Generation Uranium Inc (GEN) Actualités

Generation Uranium Inc (GEN)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

GEN Actualités

Daratumumab Granted Fast Track Designation From U.S. Food and Drug Administration

Arzerra Receives Approval in Japan

Genmab 2012 Annual Report

Genmab Announces Sale of Manufacturing Facility to Baxter

Arzerra Fourth Quarter and Full Year 2012 Net Sales Figures

Major Shareholder Announcement

Genmab Unveils a New Antibody Technology Platform: HexaBody

Genmab Reaches Third Milestone in Lundbeck Collaboration

Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

New Preliminary Efficacy Data for Daratumumab Presented at ASH

Genmab Announces DuoBody Platform Collaboration With Kyowa Hakko Kirin

CORRECTION: Genmab Announces Financial Results for the First Nine Months of 2012 and Improves 2012 Financial Guidance

Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

Arzerra Third Quarter 2012 Net Sales Figures

Major Shareholder Announcement

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application